Differences Between GH- and PRL-Cosecreting and GH-Secreting Pituitary Adenomas: a Series of 604 Cases
Authors' conclusion
GH&PRL-PAs are responsible for 20% of acromegaly cases. These tumors are more invasive, larger, and cause hypopituitarism more frequently than GH-PAs and are diagnosed at an earlier age. The biochemical cure rate is similar between both groups, but patients with GH&PRL-PAs tend to develop permanent postsurgical AVP-D more frequently.
Study context
- Population
- Patients with acromegaly who underwent pituitary surgery
- Participants
- 604 patients
- Exposure
- GH&PRL-PAs vs GH-PAs
- GH&PRL-PAsn = 130
- GH-PAsn = 474reference
- Outcome
- Clinical presentation, GH&PRL-PAs vs GH-PAs
- Follow-up
- At diagnosis
Main finding
As reported in the abstract
- Share of acromegaly cases that were GH&PRL-PAs
- 21.5% (n = 130)
- Mean age at diagnosis lower in GH&PRL-PAs than in GH-PAs
- P < .001
- Macroadenomas, GH&PRL-PAs vs GH-PAs
- 90.6% vs 77.4%; P = .001
- Invasive (trend), GH&PRL-PAs vs GH-PAs
- 33.6% vs 24.7%; P = .057
- Presurgical hypopituitarism, GH&PRL-PAs vs GH-PAs
- OR 2.8; 95% CI, 1.83-4.38
- Insulin-like growth factor upper limit of normal (ULN) levels at diagnosis, GH&PRL-PAs vs GH-PAs
- median 2.4 [IQR 1.73-3.29] vs 2.7 [IQR 1.91-3.67]; P = .023
Observational data: associations, not effects.
Safety
Permanent AVP-D
P = 0.011
Original publication
Differences Between GH- and PRL-Cosecreting and GH-Secreting Pituitary Adenomas: a Series of 604 Cases. J Clin Endocrinol Metab. Published 4 March 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →